{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:28:33Z","timestamp":1772166513935,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sarilumab (SAR), an interleukin-6 receptor inhibitor (IL-6Ri), and Janus kinase inhibitors (JAKi) are approved options for rheumatoid arthritis (RA) when methotrexate (MTX) cannot be used. Real-world evidence for MTX-free monotherapy remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a multicenter retrospective cohort study of RA patients receiving SAR or JAKi as MTX-free monotherapy. To reduce confounding, 1:1 propensity score matching was performed in the overall cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009252, 126 per group) and separately within treatment-line strata: Phase 2 first-line biologic\/targeted synthetic disease-modifying antirheumatic drugs (b\/tsDMARDs: 45 per group), Phase 3 second-line b\/tsDMARDs (53 per group), and Phase 3\u2009\n                      <jats:bold>\u2265<\/jats:bold>\n                      \u2009third-line b\/tsDMARDs (47 per group). Outcomes over 12 months included drug retention, change in Clinical Disease Activity Index (CDAI), glucocorticoid (GC) tapering and discontinuation, low disease activity (LDA, CDAI\u2009\u2264\u200910), and safety profiles. Predictors of LDA were evaluated with logistic regression. This multicenter real-world.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across matched strata by prior b\/tsDMARDs, retention and CDAI change did not differ significantly between SAR and JAKi through 12 months. When classified by cause, adverse events (AEs)-related discontinuation was higher with JAKi, yielding lower AE-specific retention. Both groups demonstrated GC sparing overtime, with a greater increase in GC discontinuation for SAR than for JAKi in Phase 2. Baseline predictors of achieving LDA at 12 months included higher C-reactive protein (CRP) and platelet count (Plt) in both groups, with additional associations of younger age and lower hemoglobin (Hb) in the SAR. In safety analyses, overall AEs were less frequent with SAR than with JAKi, driven by lower risks of infection including herpes zoster, while other categories were similarly infrequent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SAR and JAKi showed no statistically significant differences in 12-month retention or disease control in MTX-free monotherapy settings. Higher CRP and Plt with lower Hb, particularly in younger patients, identified better response to SAR and support biomarker guided selection between IL-6Ri and JAKi. In Phase 2, GC discontinuation with SAR suggests a practical strategy to reduce AEs while maintaining efficacy. Prospective studies should validate these findings and define actionable thresholds.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-025-03722-5","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T05:37:38Z","timestamp":1767418658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2810-1519","authenticated-orcid":false,"given":"Yuji","family":"Nozaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsu","family":"Itami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9011-213X","authenticated-orcid":false,"given":"Yumiko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2190-0780","authenticated-orcid":false,"given":"Takuya","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-929X","authenticated-orcid":false,"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-1964","authenticated-orcid":false,"given":"Toshihiko","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Hino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5655-6356","authenticated-orcid":false,"given":"Hirofumi","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7541-3745","authenticated-orcid":false,"given":"Kenji","family":"Mamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7895-7684","authenticated-orcid":false,"given":"Yutaro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8849-9824","authenticated-orcid":false,"given":"Tadashi","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0873-5728","authenticated-orcid":false,"given":"Takaichi","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7606-3743","authenticated-orcid":false,"given":"Jun","family":"Saegusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9360-6081","authenticated-orcid":false,"given":"Masahiro","family":"Horita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1260-586X","authenticated-orcid":false,"given":"Keiichiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-5143","authenticated-orcid":false,"given":"Koji","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3929-9751","authenticated-orcid":false,"given":"Shinya","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"3722_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320:1360\u201372.","journal-title":"JAMA"},{"key":"3722_CR2","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023\u201338.","journal-title":"Lancet"},{"key":"3722_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1759720X241283340","volume":"16","author":"PC Taylor","year":"2024","unstructured":"Taylor PC, Feist E, Pope JE, et al. What have we learnt from the Inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes? Ther Adv Musculoskelet Dis. 2024;16:1\u201319.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"3722_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13075-020-02194-z","volume":"22","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Fleischmann R, Kivitz A, et al. Efficacy and safety of sarilumab in combination with CsDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Res Ther. 2020;22:139.","journal-title":"Arthritis Res Ther"},{"key":"3722_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76:840\u20137.","journal-title":"Ann Rheum Dis"},{"key":"3722_CR6","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1136\/annrheumdis-2016-210094corr1","volume":"76","author":"Correction","year":"2017","unstructured":"Correction. Baricitinib in patients with inadequate response or intolerance to conventional synthetic dmards: results from the RA-BUILD study. Ann Rheum Dis. 2017;76:1634.","journal-title":"Ann Rheum Dis"},{"key":"3722_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152561","volume":"69","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, McDermott GC, Juge PA, et al. Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2024;69:152561.","journal-title":"Semin Arthritis Rheum"},{"key":"3722_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/14397595.2020.1869370","volume":"32","author":"S Honda","year":"2022","unstructured":"Honda S, Sakai R, Inoue E, et al. Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: results from a Japanese multi-institutional retrospective study. Mod Rheumatol. 2022;32:16\u201323.","journal-title":"Mod Rheumatol"},{"key":"3722_CR9","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/1756-185X.14207","volume":"24","author":"D Vijaykumar","year":"2021","unstructured":"Vijaykumar D, Dhir V, Jain S, et al. Assessing methotrexate intolerance and its prevalence in rheumatoid arthritis: development and validation of the MISA questionnaire. Int J Rheum Dis. 2021;24:1294\u2013301.","journal-title":"Int J Rheum Dis"},{"key":"3722_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495\u2013507.","journal-title":"N Engl J Med"},{"key":"3722_CR11","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1136\/annrheumdis-2017-211259","volume":"76","author":"EC Keystone","year":"2017","unstructured":"Keystone EC, Taylor PC, Tanaka Y, et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis. 2017;76:1853\u201361.","journal-title":"Ann Rheum Dis"},{"key":"3722_CR12","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis & Rheumatology. 2020;72:1607\u201320.","journal-title":"Arthritis & Rheumatology"},{"key":"3722_CR13","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7:R796\u2013806.","journal-title":"Arthritis Res Ther"},{"key":"3722_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"3722_CR15","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"3722_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41\u201355.","journal-title":"Biometrika"},{"key":"3722_CR17","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB Jr. D\u2019Agostino","year":"1998","unstructured":"D\u2019Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265\u201381.","journal-title":"Stat Med"},{"key":"3722_CR18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI200420945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271\u20136.","journal-title":"J Clin Invest"},{"key":"3722_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/rheumatology\/kead299","volume":"63","author":"Y Nakayama","year":"2024","unstructured":"Nakayama Y, Watanabe R, Yamamoto W, et al. IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study. Rheumatology (Oxford). 2024;63:349\u201357.","journal-title":"Rheumatology (Oxford)"},{"key":"3722_CR20","doi-asserted-by":"publisher","first-page":"977828","DOI":"10.3389\/fimmu.2022.977828","volume":"13","author":"SZ Jiang","year":"2022","unstructured":"Jiang SZ, To JL, Hughes MR, et al. Platelet signaling at the nexus of innate immunity and rheumatoid arthritis. Front Immunol. 2022;13:977828.","journal-title":"Front Immunol"},{"key":"3722_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3109\/14397595.2014.915073","volume":"25","author":"H Matsuno","year":"2015","unstructured":"Matsuno H. Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts. Mod Rheumatol. 2015;25:38\u201342.","journal-title":"Mod Rheumatol"},{"key":"3722_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0665-7","volume":"17","author":"KL Habets","year":"2015","unstructured":"Habets KL, Trouw LA, Levarht EW, et al. Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. Arthritis Res Ther. 2015;17:209.","journal-title":"Arthritis Res Ther"},{"key":"3722_CR23","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","volume":"20","author":"F Zhang","year":"2019","unstructured":"Zhang F, Wei K, Slowikowski K, et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol. 2019;20:928\u201342.","journal-title":"Nat Immunol"},{"key":"3722_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/cells14090625","volume":"14","author":"C Zamora","year":"2025","unstructured":"Zamora C, Diaz-Torne C, et al. Platelet-derived soluble CD40L and its impact on immune modulation and anti-IL6R antibody treatment outcome in rheumatoid arthritis. Cells. 2025;14:625.","journal-title":"Cells"},{"key":"3722_CR25","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/annrheumdis-2019-215987","volume":"79","author":"IH Shafran","year":"2020","unstructured":"Shafran IH, Alasti F, Smolen JS, et al. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2020;79:874\u201382.","journal-title":"Ann Rheum Dis"},{"key":"3722_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/03009742.2021.1947005","volume":"51","author":"Y Nakayama","year":"2022","unstructured":"Nakayama Y, Hashimoto M, Watanabe R, et al. Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study. Scand J Rheumatol. 2022;51:431\u201340.","journal-title":"Scand J Rheumatol"},{"key":"3722_CR27","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/acr.22765","volume":"68","author":"J Wang","year":"2016","unstructured":"Wang J, Devenport J, Low JM, et al. Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:882\u20135.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3722_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.semarthrit.2017.03.024","volume":"47","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Palmer JL, Kremer J, Bingham CO 3. Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis. Semin Arthritis Rheum. 2017;47:165\u20139.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03722-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:50:46Z","timestamp":1770645046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-025-03722-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3722"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03722-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7787959\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This multicenter observational study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of Kindai University School of Medicine (Approval No. 31\u2009\u2212\u2009020), the coordinating institution. Ethics approval was also obtained from the institutional review boards of Kobe University Graduate School of Medicine, Osaka Metropolitan University, Osaka Medical and Pharmaceutical University, Miyazaki Zenjinkai Hospital, Izumi City General Medical Center, Seirei Hamamatsu General Hospital, Tenri Hospital, and Okayama University Hospital. The requirement for written informed consent was waived at Kindai University via an opt-out process disclosed on the hospital website. At all other institutions, written informed consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final manuscript and the submission to this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YN has received speaker fees from AbbVie, Astellas, Asahi Kasei, Chugai, Eisai, Eli Lilly, GlaxoSmithKline, and Mitsubishi Tanabe.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}